Updated: 3 - As the wave of biotech company IPOs surges, City Therapeutics submits a US initial public offering (IPO) application.
路透社2026/09/24 22:36Analyst commentary added in paragraphs 3, 4, and 9, along with charts
Reuters, September 24 - City Therapeutics filed for an initial public offering (IPO) in the United States on Thursday, joining a host of biotechnology companies rushing to take advantage of the autumn IPO window.
As investor interest in the biotech sector is rekindling, the field has become one of the main themes in this year's IPO market. However, the autumn listing boom has yet to gain strong momentum, as risk appetite is dampened by surging bond yields, tightening monetary policy, and concerns surrounding AI-driven trades.
"For a biotech company with promising therapies, minor interest rate fluctuations or macro headwinds don't make much difference," said Matt Kennedy, Senior Strategist at Renaissance Capital, an institution focused on IPO research and ETFs.
"Ultimately, it's all about whether the drug candidates can succeed in clinical trials. There's also the market sentiment for the biotech sector—while other areas in the IPO market are facing pressure, sentiment in this sector remains elevated."
Other drug developers Retension Pharmaceuticals, TRex Bio (link) and Iambic Therapeutics (link) also announced their US IPO filings earlier this month, which is a key step before kicking off roadshows.
New drug developer ADARx Pharmaceuticals, focused on RNA medicines for rare diseases, is expected to list on Friday (link).
Founded in 2023, City Therapeutics is advancing a pipeline of RNA therapies targeting rare diseases. Its most advanced candidate, CITY-FXI, is currently in early-stage clinical trials for the treatment of thrombosis—the formation of harmful blood clots within blood vessels.
This Cambridge, Massachusetts-based company has raised about $238.8 million since its establishment from life sciences investors including ARCH Venture Partners, Fidelity Management & Research Company, Invus, and Viking Global Investors.
"In addition to positive clinical results, IPO investors are looking for companies to forge partnerships with large pharmaceutical companies, which increases the likelihood of future acquisitions," said Kennedy of Renaissance Capital.
Goldman Sachs, Jefferies, Stifel, and Oppenheimer are underwriters for the offering. The company will list on Nasdaq under the symbol "CTY".
(To assist non-native English speakers, Reuters provides automated translations of its reports in several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them for readers' convenience only. Reuters bears no responsibility for any damage or loss arising from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."
Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.
Chun purchased 7,186 ETH worth $11.74 million


Philadelphia Fed President Paulson: Consecutive rate hikes not ruled out, but emphasizes “measured pace”
Philadelphia Fed President Paulson stated that he is willing to consider consecutive rate hikes to curb inflation, but emphasized that this should be done at a "prudent" pace. He indicated that interest rates need to continue rising and remains "open" to consecutive hikes, but refused to commit to a specific pace. Currently, the U.S. economy is performing well and the labor market remains strong, providing room for tighter policy, but tackling inflation remains the top priority.
